Understanding human immunodeficiency virus type 1 and hepatitis C virus coinfection

Current HIV Research

Volumn 4, Issue 1, 2006, Pages 21-30

  Tan, Yee Joo ^a   Lim, Seng Gee ^a   Hong, Wanjin ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Hepatitis C virus; HIV HCV coinfection; Human immunodeficiency virus type 1; Immune evasion; Quasispecies; Viral host interactions

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CD209 ANTIGEN; CD81 ANTIGEN; CYCLIN DEPENDENT KINASE 2; DEAD BOX PROTEIN; GAG PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRASE; INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NEF PROTEIN; PEGINTERFERON; POL PROTEIN; PROTEIN P53; PROTEINASE; REV PROTEIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR AP 1; UNINDEXED DRUG; VIF PROTEIN; VIRUS RNA; VPR PROTEIN; VPU PROTEIN; VIRUS PROTEIN;

DENDRITIC CELL; DRUG COMPETITION; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SPECIES DIVERSITY; SUPERINFECTION; TREATMENT FAILURE; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; CLASSIFICATION; GENETICS; HEPATITIS C VIRUS; IMMUNOLOGY; METABOLISM; PATHOGENICITY; VIROLOGY;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; VIRAL PROTEINS;

EID: 33644918602     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016206775197600     Document Type: Review

References (158)

1. Abe K, Ikeda M, Dansako H, Naka K, Shimotohno K, Kato N. (2005). cDNA microarray analysis to compare HCV subgenomic replicon cells with their cured cells. Virus Research. 107: 73-81.
2. Aizaki H, Lee KJ, Sung VM, Ishiko H, Lai MM. (2004). Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology. 324: 450-461.
3. Alatrakchi N, Graham CS, He Q, Sherman KE, Koziel MJ. (2005). CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. Journal of Infectious Diseases. 191: 702-709.
4. Ameisen JC, Pleskoff O, Lelièvre J-D, De Bels F. (2003). Subversion of cell survival and cell death: viruses as enemies, tools, teachers and allies. Cell Death and Differentiation. 10: S3-S6.
5. Anderson JL, Hope TJ. (2003). Recent Insights into HIV Accessory Proteins. Current Infectious Disease Report. 5: 439-450.
6. Andersen JL, Planelles V. (2005). The role of Vpr in HIV-1 pathogenesis. Current HIV Research. 3: 43-51.
7. Anthony DD, Yonkers NL, Post AB, Asaad R, Heinzel FP, Lederman MM, Lehmann PV, Valdez H. (2004). Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. Journal of Immunology. 172: 4907-4916.
8. Aoki H, Hayashi J, Moriyama M, Arakawa Y, Hino O. (2000). Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1. Journal of Virology. 74: 1736-1741.
9. Arima N, Kao CY, Licht T, Padmanabhan R, Sasaguri Y, Padmanabhan R. (2001). Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. Journal of Biological Chemistry. 276: 12675-12684.
10. Babik JM, Holodniy M. (2003). Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. Journal of Virology. 77: 1940-1950.
11. Bailey J, Blankson JN, Wind-Rotolo M, Siliciano RF. (2004). Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. Current Opinion in Immunology. 16: 470-476.
12. Bantel H, Schulze-Osthoff K. (2003). Apoptosis in hepatitis C virus infection. Cell Death and Differentiation. 10: S48-S58.
13. Bartenschlager R, Frese M, Pietschmann T. (2004). Novel insights into hepatitis C virus replication and persistence. Advances in Virus Research. 63: 71-180.
14. Beitzel B, Bushman F. (2003). Construction and analysis of cells lacking the HMGA gene family. Nucleic Acids Research. 31: 5025-5032.
15. Belmonte L, Bare P, de Bracco MM, Ruibal-Ares BH. (2003). Reservoirs of HIV replication after successful combined antiretroviral treatment. Current Medicinal Chemistry. 10: 303-312.
16. Benedict CA., Norris PS, Ware CF. (2002). To kill or be killed: viral evasion of apoptosis. Nature Immunology. 3: 1013-1018.
17. Berger EA, Murphy PM, Farber JM. (1999). Chemokine receptors asHIV-1 coreceptors: roles in viral entry, tropism, and disease. Annual Review in Immunology. 17: 657-700.
18. Berkhout B. (1999). HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. Journal of Biomedical Science. 6: 298-305.
19. Blankson JN, Persaud D, Siliciano RF. (2002). The challenge of viral reservoirs in HIV-1 infection. Annual Review in Medicine. 53: 557-593.
20. Borgia G, Reynaud L, Gentile I, Piazza M. (2003). HIV and hepatitis C virus: facts and controversies. Infection. 31: 232-240.
21. Bour S, Strebel K. (2003). The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes & Infection. 5: 1029-1039.
22. Braaten D, Aberham C, Franke EK, Yin L, Phares W, Luban J. (1996). Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophitin A. Journal of Virology. 70: 5170-5176.
23. Braitstein P, Palepu A, Dieterich D, Benhamou Y, Montaner JS. (2004). Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS. 18: 2221-2234.
24. Campbell SM, Crowe SM, Mak J. (2002). Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS. 16: 2253-2261.
25. Canchis PW, Yee HT, Fiel MI, Dieterich DT, Liu RC, Chiriboga L, Jacobson IM, Edlin BF, Talal AH. (2004). Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. Journal of Acquired Immune Deficiency Syndromes. 37: 1125-1131.
26. Canobio S, Guilbert CM, Troesch M, Samson J, Lemay M, Pelletier VA, Bernard-Bonnin AC, Kozielski I, Lapointe N, Martin SR, Soudeyns H. (2004). Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. Journal of Clinical Microbiology. 42: 4365-4369.
27. Carrère-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C., Penin F, Dubuisson J. (2002). Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. Journal of Virology. 76: 3720-3730.
28. Caudai C, Pianese M, Zacchini F, Toti M, Zazzi M, Valensin PE. (2005). Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype. Journal of Clinical Virology. 32: 151-155.
29. Chen R, Quinones-Mateu ME, Mansky LM. (2004). Drug resistance, virus fitness and HIV-1 mutagenesis. Current Pharmaceutical Design. 10: 4065-4070.
30. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs Y, De Clercq E, Debyser Z. (2003). HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. Journal of Biological Chemistry. 278: 372-381.
31. Choukhi A, Ung S, Wychowski C, Dubuisson J. (1998). Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins. Journal of Virology. 72: 3851-3858.
32. Clementi M. (2004). Can modulation of viral fitness represent a target for anti-HTV-1 strategies? New Microbiology. 27: 207-214.
33. Cocude C, Truong MJ, Billaut-Mulot 0, Delsart V, Darcissac E, Capron A, Mouton Y, Bahr GM. (2003). A novel cellular RNA helicase, RH116, differentially regulates cell growth, programmed cell death and human immunodeficiency virus type 1 replication. Journal of General Virology. 84: 3215-3225.
34. Coffin JM. (1995). HIV population dynamics in vivo: implications for génetic variation, pathogenesis, and therapy. Science. 267: 483-489.
35. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. (1998). HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 391: 397-401.
36. Craigo JK, Patterson BK, Paranjpe S, Kulka K, Ding M, Mellors J, Montelaro RC, Gupta P. (2004). Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. AIDS Research & Human Retroviruses. 20: 1196-1209.
37. Devereux HL, Brown D, Dusheiko GM, Emery VC, Lee CA. (1997). Long-term evolution of the 5'UTR and a region of NS4 containing a CTL epitope of hepatitis C virus in two haemophilic patients. Journal of General Virology. 78: 583-590.
38. Dvorin JD, Malim MH. (2003). Intracellular trafficking of HIV-1 cores: journey to the center of the cell. Current Topics in Microbiology and Immunology. 281: 179-208.
39. Eisen-Vandervelde AL, Yao ZQ, Hahn YS. (2004). The molecular basis of HCV-mediated immune dysregulation. Clinical Immunology. 111: 16-21.
40. Fang J, Acheampong E, Dave R, Wang F, Mukhtar M, Pomerantz RJ. (2005).The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes. Virology. 336: 299-307.
41. Fang J, Kubota S, Yang B, Zhou N, Zhang H, Godbout R, Pomerantz RJ. (2004). A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. Virology. 330: 471-480.
42. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. (2000). The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 288: 339-344.
43. Farnet CM, Bushman FD. (1997). HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell. 88: 483-492.
44. Ferrantelli, F., Cafaro A. and Ensoli, B, (2004). Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Current Opinion in Biotechnology. 15: 543-556.
45. Fimia GM, Tripodi M, Alonzi T. (2003). Transgenic models for Hepatitis C virus pathogenesis. Cell Death and Differentiation. 10:S16-S18.
46. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottoin A, Levy S, McKeating JA. (1999). Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. Journal of Virology. 73: 6235-6244.
47. Franke EK, Yuan HE, Luban J. (1994). Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 372: 359-362.
48. Freed EO. (2004). HIV-1 and the host cell: an intimate association. Trends in Microbiology. 12: 170-177.
49. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. (2001). Immunopathogenesis of hepatitis C virus infection. Immunology Cell Biology. 79: 515-536.
50. Fujii R, Okamoto M, Aratani S, Oishi T, Ohshima T, Taira K, Baba M, Fukamizu A, Nakajima T. (2001). A role of RNA helicase A in cis-acting transactivation response element-mediated transcriptional regulation of human immunodeficiency virus type 1. Journal of Biological Chemistry. 276: 5445-5451.
51. Gale MJ Jr, Korth MJ, Katze MG. (1998). Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clinical and Diagnostic Virology. 10:157-162.
52. Garrus JE, von Schwedler UK, Pomillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG, Sundquist WL (2001). Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 107: 55-65.
53. Giannini C, Bréchot C (2003). Hepatitis C virus biology. Cell Death and Differentiation. 10: S27-S38.
54. Goh PY, Tan YJ, Lim SP, Tan YH, Lim SG, Fuller-Pace F, Hong W. (2004). Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication. Journal of Virology. 78: 5288-5298.
55. Gonzalez ME, Carrasco L (2003). Viroporins. FEBS Letters. 552: 28-34.
56. Gonzalez-Peralta RP, Qian K, She JY, Davis GL, Ohno T, Mizokami M, Lau JY. (1996). Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. Journal of Medical Virology. 49: 242-247.
57. Goodman ZD, Ishak KG (1995). Histopathology of hepatitis C virus infection. Seminars in Liver Disease. 15: 70-81.
58. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, Horsburgh R, Craven, D, Sherman KE, Koziel MJ. (2004). Comparison of HCV-Specific Intrahepatic CD4-T Cells in HIV/HCV Versus HCV. Hepatology. 40: 125-132.
59. Greene WC, Peterlin BM. (2002). Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nature Medicine. 8: 673-680.
60. Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, Harris MP, Rowlands DJ. (2003). The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Letters. 535: 34-38.
61. Gulzar N, Copeland KF. (2004). CD8+ T-cells: function and response to HIV infection. Current HIV Research. 2: 23-37.
62. Guyader M, Kiyokawa E, Abrami L, Turelli P, Trono D. (2002). Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. Journal of Virology. 76: 10356-10364.
63. Hadziyannis SJ, Koskinas JS. (2004). Differences in epidemiology, liver disease and treatment response among HCV genotypes. Hepatology Research 29: 129-135.
64. Hahn YS (2003). Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Current Opinion in Immunology. 15: 443-449.
65. Haorah J, Heilman D, Diekmann C, Osna N, Donohue TM Jr, Ghorpade A, Persidsky Y. (2004). Alcohol and HIV decrease proteasome and immunoproteasome function in macrophages: implications for impaired immune function during disease. Cell Immunology. 229: 139-148.
66. Hay S, Kannourakis G. (2002). A time to kill: viral manipulation of the cell death program. Journal of General Virology. 83: 1547-1564.
67. Hilleman MR. (2004). Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proceedings of the National Academy of Sciences of the United States of America. 101 (Suppl 2): 14560-14566.
68. Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K. (1994). Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology. 20: 1144-1151.
69. Hsieh TY, Matsumoto M, Chou HC, Schneider R, Hwang SB, Lee AS, Lai MM. (1998). Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K. Journal of Biological Chemistry. 273: 17651-17659.
70. Jin DY, Wang HL, Zhou Y, Chun AC, Kibler KV, Hou YD, Kung H, Jeang KT. (2000). Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. EMBO Journal. 19: 729-740.
71. Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP. (1994). Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science. 266: 2002-2006.
72. Khalih M, Proietti N. (2004). Treatment of the hepatitis C virus in patients coinfected with HIV. Gastroenterology Clinics of North America. 33: 479-496.
73. Khu YL, Tan YJ, Lim SG, Hong W, Goh PY. (2004). Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. Biochemical Journal. 384: 401-409.
74. Kim AY, Lauer GM, Ouchi K, Addo MM, Lucas M, Wiesch JS, Timm J, Boczanowski M, Duncan JE, Wurcel AG, Casson D, Chung RT, Draenert R, Klenerman P, Walker BD (2005). The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood. 105: 1170-1178.
75. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. (2000). Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. Journal Clinical Investigation. 106:1239-1249.
76. Klenerman P, Wu Y, Phillips R. (2002). HIV: current opinion in escapology Current Opinion in Microbiology. 5: 408-413.
77. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C. (1995). Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology. 22: 30-35.
78. Kyono K, Miyashiro M, Taguchi I. (2002). Human eukaryotic initiation factor 4AII associates with hepatitis C virus NS5B protein in vitro. Biochemical and Biophysical Research Communications. 292: 659-666.
79. Lambotte O, Deiva K, Tardieu M. (2003). HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathology. 13: 95-103.
80. Lanzavecchia A, Sallusto F. (2001). The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Current Opinion in Immunology. 13: 291-298.
81. Larder BA, Kemp SD. (1989). Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 246: 1155-1158.
82. Laskus T, Radkowski M, Jablonska J, Kibler K, Wilkinson J, Adair D, Rakela J. (2004). Human immunodeficiency virus facilitates infection/ replication of hepatitis C virus in native human macrophages. Blood. 103: 3854-3859.
83. Laskus T, Radkowski M, Piasek A, Nowicki M, Horban A, Cianciara J, Rakela J. (2000). Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. Journal of Infectious Diseases. 181: 442-448.
84. Lauer GM, Nguyen TN, Day CL, Robbins GK, Flynn T, McGowan K, Rosenberg E S, Lucas M, Klenerman P, Chung RT, Walker BD. (2002). Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two Persistent viruses. Journal of Virology. 76: 2817-2826.
85. Lauer GM, Walker BD. (2001). Hepatitis C virus infection. New England Journal of Medicine. 345: 41-52.
86. Lee MS, Craigie R. (1994). Protection of retroviral DNA from autointegration: involvement of a cellular factor. Proceedings of the National Academy of Sciences of the United States of America. 91:9823-9827.
87. Li J, Tang H, Mullen TM, Westberg C, Reddy TR, Rose DW, Wong-Staal F. (1999). A role for RNA helicase A in posttranscriptional regulation of HIV type 1. Proceedings of the National Academy of Sciences of the United States of America. 96: 709-714.
88. Li L, Yoder K, Hansen MS, Olvera J, Miller MD, Bushman FD. (2000). Retroviral cDNA integration: stimulation by HMG I family proteins. Journal of Virology. 74: 10965-10974.
89. Lieberman J, Manjunath N, Shankar P. (2002). Avoiding the kiss of death: how HIV and other chronic viruses survive. Current Opinion in Immunology. 14: 478-486.
90. Lin CW, Engelman A. (2003). The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes. Journal of Virology. 77: 5030-5036.
91. Lu W, Lo SY, Chen M, Wu KJ, Fung YK, Ou J-H. (1999). Activation of p53 tumor suppressor by hepatitis C virus core protein. Virology. 264: 134-141.
92. Macdonald A, Harris M. (2004). Hepatitis C virus NS5A: tales of a promiscuous protein. Journal of General Virology. 85: 2485-2502.
93. Macias J, Pineda JA, Lozano F, Corzo JE, Ramos A, Leon E, Garcia-Garcia JA, Fernandez-Rivera J, Mira JA, Gomez-Mateos J. (2003). Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naive patients coinfected with human immunodeficiency virus and hepatitis C virus. European Journal of Clinical Microbiology and Infectious Diseases. 22: 675-680.
94. Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clereq E, Debyser Z, Engelborghs Y. (2003). LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. Journal of Biological Chemistry. 278: 33528-33539.
95. Mamiya N, Worman HJ. (1999). Hepatitis C virus core protein binds to a DEAD box RNA helicase. Journal of Biological Chemistry. 274:15751-15756.
96. Manes S, del Real G, Martinez-A C. (2003). Pathogens: raft hijackers. Nature Review in Immunology. 3: 557-568.
97. Mao Q, Ray SC, Laeyendecker O, Ticehurst JR, Strathdee SA, Vlahov D, Thomas DL (2001). Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies. Journal of Virology. 75: 3259-3267.
98. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. (2003). Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 114: 21-31.
99. Marin M, Rose KM, Kozak SL, Kabat D. (2003). HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Medicine. 9: 1398-1403.
100. Martin-Serrano J, Zang T, Bieniasz PD. (2001). HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nature Medicine. 7: 1313-1319.
101. Matsumoto M, Hsieh TY, Zhu N, VanArsdale T, Hwang SB, Jeng KS, Gorbalenya AE, Lo SY, Ou JH, Ware CF, Lai MM. (1997). Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin- receptor. Journal of Virology. 71: 1301-1309.
102. Matto M, Rice CM, Aroeti B, Glenn JS. (2004). Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts. Journal of Virology. 78: 12047-12053.
103. Menendez-Arias L, Martinez MA, Quinones-Mateu ME, Martinez-Picado J. (2003). Fitness variations and their impact on the evolution of antiretroviral drug resistance. Current Drug Targets - Infectious Disorders. 3: 355-371.
104. Montal M. (2003). Structure-function correlates of Vpu, a membrane protein of HIV-1. FEBS Letters. 552: 47-53.
105. Moreno L, Quereda C, Moreno A, Perez-Elias MJ, Antela A, Casado JL, Dronda F, Mateos ML, Barcena R, Moreno S. (2004). Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS. 18: 67-73.
106. Munshi N, Balasubramanian A, Koziel M, Garju RK, Groopman JE. (2003). Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. Journal of Infectious Diseases. 188: 1192-1204.
107. Nakamoto Y, Kaneko S. (2003). Mechanisms of viral hepatitis induced liver injury. Current Molecular Medicine. 3:537-544.
108. Neumann-Haefelin C, Bluma HE, Chisaii FV, Thimme R. (2005). T cell response in hepatitis C virus infection. Journal of Clinical Virology. 32: 75-85.
109. Owsianka AM, Patel AH. (1999). Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. Journal of Virology. 257: 330-340.
110. Pachiadakis, I., Pollara, G., Chain, BM, Naoumov NV. (2005). Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infectious Diseases. 5: 296-304.
111. Park JS, Yang JM, Min MK. (2000). Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochemical and Biophysical Research Communications. 267: 581-587.
112. Pavio N, Lai MM. (2003). The hepatitis C virus persistence: how to evade the immune system? Journal of Biosciences. 28: 287-304.
113. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, Koike K, Pessayre D, Chapman J, Barba G et al. (2002). Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB Journal. 16: 185-194.
114. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. (2004). Hepatitis C virus persistence after spontaneous or treatment induced resolution of hepatitis C. Journal of Virology. 78: 5867-5874.
115. Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G, Barber GN, Levy DE, Mukaida N, Gretch DR. (2001). Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. Journal of Virology. 75:6095-6106.
116. Poynard T, Yuen MF, Ratziu V, Lai CL. (2003). Viral hepatitis C. Lancet. 362: 2095-2100.
117. Racanelli V, Rehermann B. (2003). Hepatitis C virus infection: when silence is deception. Trends in Immunology. 24: 456-464.
118. Radkowski M, Bednarska A, Horban A, Stanczak J, Wilkinson J, Adair DM, Nowicki M, Rakela J, Laskus T. (2004). Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-alpha and interleukin 8. Journal of General Virology. 85: 47-59.
119. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T. (2005). Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 41: 106-114.
120. Ray RB, Steele R, Meyer K, Ray R. (1997). Transcriptional repression of p53 promoter by hepatitis C virus core protein. Journal of Biological Chemistry. 272: 10983-10986.
121. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. (1999). Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. Journal of Virology. 73: 2938-2946.
122. Roque-Afonso AM, Robain M, Simoneau D, Rodriguez-Mathieu P, Gigou M, Meyer L, Dussaix E. (2002). Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus. Journal of Infectious Diseases. 185: 728-733.
123. Sabile A, Perlemuter G, Bono F, Kohara K, Demaugre F, Kohara M, Matsuura Y, Miyamura T, Brechot C, Barba G. (1999). Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology. 30: 1064-1076.
124. Schuppan D, Krebs A, Bauer M, Hahn EG. (2003). Hepatitis C and liver fibrosis. Cell Death and Differentiation. 10: S59-S67.
125. Sheehy AM, Gaddis NC, Mahin MH. (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Medicine. 9: 1404-1407.
126. Sherman KE. (2004). HCV and HIV: a tale of two viruses. Reviews in Gastroenterological Disorders. 4(Suppl 1): S48-S54.
127. Sherman KE, Andreatta C, O'Brien J, Gutierrez A, Harris R. (1996). Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology. 23: 688-694.
128. Shi ST, Lee KJ, Aizaki H, Hwang SB, Lai MM. (2003). Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. Journal of Virology. 77: 4160-4168.
129. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM. (2002). Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology. 292: 198-210.
130. Shoukry NH, Cawthon AG, Walker CM. (2004). Cell-mediated immunity and the outcome of hepatitis C virus infection. Annual Review of Microbiology. 58: 391-424.
131. Shrivastava A, Manna SK, Ray R, Aggarwal BB. (1998). Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. Journal of Virology. 72: 9722-9728.
132. Silverman E, Edwalds-Gilbert G, Lin RJ. (2003). DExD/H-box proteins and their partners: helping RNA helicases unwind. Gene. 312: 1-16.
133. Simmonds P. (2004). Genetic diversity and evolution of hepatitis C virus-15 years on. Journal of General Virology. 85: 3173-3188.
134. Steinman RM, Nussenzweig MC. (2002). Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proceedings of the National Academy of Sciences of the United States of America. 99: 351-358.
135. Stopak K, de Noronha C, Yonemoto W, Greene WC. (2003). HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Molecular Cell. 12: 591-601.
136. Strebel K. (2003). Virus-host interactions: role of HIV proteins Vif, Tat, and Rev. AIDS. 17: S25-S34.
137. Sulkowski MS, Thomas DL. (2003). Hepatitis C in the HIV-Infected Person. Annals of Internal Medicine. 138: 197-207.
138. Suzuki Y, Craigie R. (2002). Regulatory mechanisms by which barrier-to-autointegration factor blocks autointegration and stimulates intermolecular integration of Moloney murine leukemia virus preintegration complexes. Journal of Virology. 76: 12376-12380.
139. Tan S-L, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ, Katze MG. (1999). NS5A, a non-structural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proceedings of the National Academy of Sciences of the United States of America. 96: 5533-5538.
140. Tanner NK, Linder P. (2001). DExD/H box RNA helicases: from generic motors to specific dissociation functions. Molecular Cell. 8: 251-562.
141. Tellinghuisen TL and Rice CM. (2002). Interaction between hepatitis C virus proteins and host cell factors. Current Opinion in Microbiology. 5: 419-427.
142. Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H, Hayakawa T. (1997). Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. Journal of Hepatology. 26: 975-982.
143. Trkola A. (2004). HIV-host interactions: vital to the virus and key to its inhibition. Current Opinion in Microbiology. 7, 555-559.
144. Tu H, Gao L, Shi ST, Taylor DR, Yang T, Mircheff AK, Wen Y, Gorbalenya AE, Hwang SB, Lai MMC. (1999). Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. Virology. 263: 30-41.
145. Verani A, Gras G, Pancino G. (2005). Macrophages and HIV-1: dangerous liaisons. Molecular Immunology. 42: 195-212.
146. Verucchi G, Calza L, Manfredi R, Chiodo F. (2004). Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection. 32: 33-46.
147. Voiculescu CL, Balasoiu M, Turculeanu A, Radu C, Avramescu C, Radu E. (1996). Different patterns of some systemic immunological cell markers in HIV only, and HIV/hepatitis C-infected children. Pediatric AIDS/HIV infection. 7: 31-36.
148. Wang F, Yoshida I, Takamatsu M, Ishido S, Fujita T, Oka K, Hotta H (2000). Complex formation between hepatitis C virus core protein and p21Waf1/Cip1/Sdi1. Biochemical and Biophysical Research Communications. 273: 479-484.
149. Waxman L, Whitney M, Pollok BA, Kuo LC, Darke PL. (2001). Host cell factor requirement for hepatitis C virus enzyme maturation. Proceedings of the National Academy of Sciences of the United States of America. 98: 13931-13935.
150. Wilflingseder D., Banki Z., Dierich, MP., Stoiber H. (2005). Mechanisms promoting dendritic cell-mediated transmission of HIV. Molecular Immunology. 42: 229-237.
151. Wunschmann S, Medh JD, Klinzmann D, Schmidt VVN, Stapleton JT. (2000). Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. Journal of Virology. 74: 10055-10062.
152. Xu Z, Choi J, Yen TS, Lu W, Strohecker A, Govindarajan S, Chien D, Selby MJ, Ou J. (2001). Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO Journal. 20: 3840-3848.
153. Yedavalli VS, Neuveut C, Chi YH, Kleiman L, Jeang KT. (2004). Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell. 119: 381-392.
154. Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES (2005). Hemophilia Growth and Development Study. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. Journal of Infectious Diseases. 191: 4-10.
155. You LR, Chen CM, Yeh TS, Tsai TY, Mai RT, Lin CH, Lee YH. (1999). Hepatitis C virus core protein interacts with cellular putative RNA helicase. Journal of Virology. 73:2841-2853.
156. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. (2003). Induction of APOBEOG ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 302: 1056-1060.
157. Zaccarelli M, Tozzi V, Perno CF, Antinori A. (2004). The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage? Current HIV Research. 2: 283-292.
158. Zhu N. Khoshnan A, Schneider R, Matsumoto M. Dennert G, Ware C, Lai MMC, (1998). Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. Journal of Virology. 72:3691-3697.